BioLife Solutions Inc (NASDAQ:BLFS) VP James Mathers Sells 2,500 Shares

BioLife Solutions Inc (NASDAQ:BLFS) VP James Mathers sold 2,500 shares of the stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $16.69, for a total transaction of $41,725.00. Following the transaction, the vice president now owns 19,884 shares in the company, valued at $331,863.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

James Mathers also recently made the following trade(s):

  • On Thursday, October 31st, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $16.89, for a total transaction of $42,225.00.
  • On Tuesday, October 29th, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $17.31, for a total transaction of $43,275.00.
  • On Tuesday, October 15th, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $16.06, for a total transaction of $40,150.00.
  • On Thursday, October 17th, James Mathers sold 2,693 shares of BioLife Solutions stock. The shares were sold at an average price of $16.42, for a total transaction of $44,219.06.
  • On Wednesday, October 2nd, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $15.78, for a total transaction of $39,450.00.
  • On Wednesday, September 18th, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $20.95, for a total transaction of $52,375.00.
  • On Thursday, September 5th, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $20.11, for a total transaction of $50,275.00.
  • On Tuesday, September 3rd, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $20.07, for a total transaction of $50,175.00.
  • On Tuesday, August 20th, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $20.06, for a total transaction of $50,150.00.
  • On Thursday, August 22nd, James Mathers sold 7,500 shares of BioLife Solutions stock. The shares were sold at an average price of $20.45, for a total transaction of $153,375.00.

Shares of BioLife Solutions stock traded up $0.16 on Thursday, hitting $14.75. The stock had a trading volume of 521,600 shares, compared to its average volume of 175,713. The company has a quick ratio of 7.71, a current ratio of 9.42 and a debt-to-equity ratio of 0.02. BioLife Solutions Inc has a one year low of $9.15 and a one year high of $22.44. The stock has a market cap of $340.37 million, a price-to-earnings ratio of 105.36 and a beta of 1.35. The stock’s 50-day simple moving average is $16.47 and its two-hundred day simple moving average is $17.74.

Institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. bought a new position in shares of BioLife Solutions in the second quarter worth approximately $30,000. Alpine Woods Capital Investors LLC bought a new position in shares of BioLife Solutions in the second quarter worth approximately $170,000. Morgan Stanley grew its holdings in shares of BioLife Solutions by 17.5% in the second quarter. Morgan Stanley now owns 11,506 shares of the medical equipment provider’s stock worth $195,000 after purchasing an additional 1,713 shares during the last quarter. Menta Capital LLC bought a new position in shares of BioLife Solutions in the second quarter worth approximately $202,000. Finally, Charles Schwab Investment Management Inc. bought a new position in shares of BioLife Solutions in the second quarter worth approximately $283,000. Hedge funds and other institutional investors own 45.62% of the company’s stock.

A number of research analysts have commented on the stock. Zacks Investment Research upgraded shares of BioLife Solutions from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a research report on Thursday. BidaskClub cut shares of BioLife Solutions from a “strong-buy” rating to a “buy” rating in a report on Thursday. Maxim Group set a $26.00 target price on shares of BioLife Solutions and gave the stock a “buy” rating in a report on Tuesday, September 17th. Northland Securities raised their target price on shares of BioLife Solutions from $18.00 to $22.00 and gave the stock an “outperform” rating in a report on Wednesday, September 4th. Finally, HC Wainwright started coverage on shares of BioLife Solutions in a report on Monday, July 22nd. They issued a “buy” rating and a $23.00 target price on the stock. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $18.40.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Further Reading: What are the reasons investors use put options?

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.